AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03098238 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sample
Description: Biological sampling of two citrate tubes (18 ml) during a normal blood
Study NCT02042391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc consolidation
Description: Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
Study NCT06023134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
Study NCT02042391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc combined with CHOP chemotherapy
Description: Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
Study NCT02042391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
Description: Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
Study NCT02459054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynCardia 50cc temporary Total Artificial Heart (TAH-t)
Description: Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
Study NCT03551249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS)
Description: FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
Study NCT02487498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Study NCT02487498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
Study NCT02487498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (umeclidinium/vilanterol )
Description: Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
Study NCT02487498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (QVA149)
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Study NCT02014818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoCr-EES
Study NCT06023134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterization
Description: Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload.
Study NCT04294992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
Study NCT03691311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Two injections on days 1 and 8 previous to surgery breast cancer excision
Study NCT03834974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safety Social Media Challenge
Description: Participants will attend a webinar to learn how to create effective social media posts about sun safety and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should include a sun safety message (e.g., promoting sunscreen use and protective clothing/hats or discouraging risk behaviors like tanning and burning). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
Study NCT04294992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
Study NCT06072404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OxigenOzone_Insufflation
Description: intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
Study NCT02000830 — intervention group
Intervention type: DRUG
Intervention: Stannsoporfin
Description: Stannsoporfin administered by intramuscular (IM) injection
Study NCT03834974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Health Social Media Challenge
Description: Participants will attend a webinar to learn how to create effective social media posts about using technology to get healthy and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should mention some way that technology (e.g., mobile apps, wearables) can be used to promote a healthy habit (e.g., diet, exercise). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
Study NCT02830113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
Study NCT04828213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)
Description: The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
Study NCT04828213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance
Description: The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
Study NCT04150211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal Exten(d) vs Placebo
Description: Supplementation during 4 weeks
Study NCT04150211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polyherbal Exten(d) vs Placebo
Description: Supplementation during 4 weeks
Study NCT03411980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Single oral dose (1 x 2 mg immediate-release, film-coated tablet)
Study NCT01065870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine, capecitabine, and docetaxel
Description: 6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.
Study NCT01065870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, capecitabine, docetaxel followed by radiotherapy
Description: 6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm.
Study NCT00177853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
Study NCT02524379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
Study NCT00177853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
Study NCT00177853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concurrent radiotherapy
Description: 50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
Study NCT03481101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/CT
Description: 3 extra scans with FDG-PET/CT and 4 blood samples
Study NCT03211780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Electric LOGIQ E9 ultrasound system
Description: Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
Study NCT04619329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSMs-TACE
Description: TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)
Study NCT04619329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of HCC
Study NCT04619329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Surgical Resection of HCC
Study NCT01704690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 and Paclitaxel
Description: S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
Study NCT01704690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Cisplatin
Description: The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
Study NCT01704690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU and Cisplatin
Description: The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
Study NCT03815799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae Block
Description: A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. 40 ml bupivacaine/lidocaine mixture will be injected into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
Study NCT03815799 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive meperidine 0.5 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
Study NCT04158102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension
Description: Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL
Study NCT01511874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIGARD 22.5mg
Description: a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
Study NCT00150800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 10 mg and 25 mg~* Route of Administration: Oral
Study NCT03410095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI, cognitive testing, bloodwork
Description: Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease.
Study NCT03263481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraductal secretin test (IDST)
Description: If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
Study NCT03281499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: da Vinci Surgical System Model IS4000
Description: tailored radiotherapy regimen following transoral robotic surgery
Study NCT02802579 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard protocol
Description: tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
Study NCT02802579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enhanced protocol
Description: tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
Study NCT02802579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enhanced obesity protocol
Description: tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
Study NCT01933529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA 290
Description: ARA 290 is injected s.c. once daily during the study period
Study NCT01573065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling intervention with rapid HIV testing
Description: Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
Study NCT01933529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARA 290
Description: ARA 290 is injected s.c. once daily during the study period
Study NCT02773121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Trainer-guided at-home behavioral intervention
Study NCT02773121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Trainer-guided at-home behavioral intervention
Study NCT02689752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
Study NCT04708795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP701
Description: Preparation of Cannabis flowers (Cannabis flos)
Study NCT01090765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Study NCT02000830 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Matching placebo administered by IM injection
Study NCT04728178 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid solution
Description: Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.
Study NCT04728178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid solution
Description: Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.
Study NCT04728178 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colloid solution
Description: Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
Study NCT04728178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colloid solution
Description: Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
Study NCT03417947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D bolus
Description: One single oral liquid vitamin D3 supplement of 300 000 IU
Study NCT03417947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in taste and appearance to the vitamin D bolus
Study NCT02401542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vofatamab
Study NCT02401542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vofatamab
Study NCT02401542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Study NCT03875482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
Study NCT03875482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution for risankizumab
Description: Placebo solution in prefilled syringes, self-administered subcutaneously
Study NCT01264380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Single oral dose, fasted
Study NCT01264380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Single oral dose, with high fat meal
Study NCT01264380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Continuous administration, orally twice daily
Study NCT03875625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)